鳳凰股份(600716.SH)累計出售5932.78萬份華夏證券ETF份額
格隆匯12月1日丨鳳凰股份(600716.SH)公佈,截至2020年12月1日,公司通過集中競價和大宗交易方式累計出售5932.78萬份華夏證券ETF份額,成交金額7482.51萬元。本次減持後,公司持有2.40億份華夏證券ETF份額。
公司對持有的華夏證券ETF以交易性金融資產核算。預計扣除成本和相關税費後,上述交易影響公司2020年度税後淨利潤約為985.52萬元(未經審計),約佔公司2019年度淨利潤的11.39%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.